Literature DB >> 29187645

Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy.

Leonela Amoasii1, Chengzu Long1, Hui Li1, Alex A Mireault1, John M Shelton2, Efrain Sanchez-Ortiz1, John R McAnally1, Samadrita Bhattacharyya1, Florian Schmidt3, Dirk Grimm3, Stephen D Hauschka4, Rhonda Bassel-Duby1, Eric N Olson5.   

Abstract

Duchenne muscular dystrophy (DMD) is a severe, progressive muscle disease caused by mutations in the dystrophin gene. The majority of DMD mutations are deletions that prematurely terminate the dystrophin protein. Deletions of exon 50 of the dystrophin gene are among the most common single exon deletions causing DMD. Such mutations can be corrected by skipping exon 51, thereby restoring the dystrophin reading frame. Using clustered regularly interspaced short palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9), we generated a DMD mouse model by deleting exon 50. These ΔEx50 mice displayed severe muscle dysfunction, which was corrected by systemic delivery of adeno-associated virus encoding CRISPR/Cas9 genome editing components. We optimized the method for dystrophin reading frame correction using a single guide RNA that created reframing mutations and allowed skipping of exon 51. In conjunction with muscle-specific expression of Cas9, this approach restored up to 90% of dystrophin protein expression throughout skeletal muscles and the heart of ΔEx50 mice. This method of permanently bypassing DMD mutations using a single cut in genomic DNA represents a step toward clinical correction of DMD mutations and potentially those of other neuromuscular disorders.
Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29187645      PMCID: PMC5749406          DOI: 10.1126/scitranslmed.aan8081

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  48 in total

1.  Eteplirsen therapy for Duchenne muscular dystrophy: skipping to the front of the line.

Authors:  James J Dowling
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

Review 2.  Dystrophin and muscular dystrophy: past, present, and future.

Authors:  K F O'Brien; L M Kunkel
Journal:  Mol Genet Metab       Date:  2001 Sep-Oct       Impact factor: 4.797

3.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

4.  Genome engineering using the CRISPR-Cas9 system.

Authors:  F Ann Ran; Patrick D Hsu; Jason Wright; Vineeta Agarwala; David A Scott; Feng Zhang
Journal:  Nat Protoc       Date:  2013-10-24       Impact factor: 13.491

5.  An emerging consensus on cardiac regeneration.

Authors:  Jop H van Berlo; Jeffery D Molkentin
Journal:  Nat Med       Date:  2014-12       Impact factor: 53.440

6.  Myoblast transfer in the treatment of Duchenne's muscular dystrophy.

Authors:  J R Mendell; J T Kissel; A A Amato; W King; L Signore; T W Prior; Z Sahenk; S Benson; P E McAndrew; R Rice
Journal:  N Engl J Med       Date:  1995-09-28       Impact factor: 91.245

Review 7.  The Pathogenesis and Therapy of Muscular Dystrophies.

Authors:  Simon Guiraud; Annemieke Aartsma-Rus; Natassia M Vieira; Kay E Davies; Gert-Jan B van Ommen; Louis M Kunkel
Journal:  Annu Rev Genomics Hum Genet       Date:  2015-06-04       Impact factor: 8.929

8.  FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.

Authors:  Annemieke Aartsma-Rus; Arthur M Krieg
Journal:  Nucleic Acid Ther       Date:  2016-12-08       Impact factor: 5.486

9.  A duchenne muscular dystrophy gene hot spot mutation in dystrophin-deficient cavalier king charles spaniels is amenable to exon 51 skipping.

Authors:  Gemma L Walmsley; Virginia Arechavala-Gomeza; Marta Fernandez-Fuente; Margaret M Burke; Nicole Nagel; Angela Holder; Rachael Stanley; Kate Chandler; Stanley L Marks; Francesco Muntoni; G Diane Shelton; Richard J Piercy
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

10.  Gene Therapy for Duchenne muscular dystrophy.

Authors:  Julian Ramos; Jeffrey S Chamberlain
Journal:  Expert Opin Orphan Drugs       Date:  2015-10-06       Impact factor: 0.694

View more
  85 in total

1.  AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice.

Authors:  Chady H Hakim; Nalinda B Wasala; Christopher E Nelson; Lakmini P Wasala; Yongping Yue; Jacqueline A Louderman; Thais B Lessa; Aihua Dai; Keqing Zhang; Gregory J Jenkins; Michael E Nance; Xiufang Pan; Kasun Kodippili; N Nora Yang; Shi-Jie Chen; Charles A Gersbach; Dongsheng Duan
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  RNA Splicing and Disease: Animal Models to Therapies.

Authors:  Matías Montes; Brianne L Sanford; Daniel F Comiskey; Dawn S Chandler
Journal:  Trends Genet       Date:  2018-11-19       Impact factor: 11.639

3.  CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo.

Authors:  Benjamin L Duchêne; Khadija Cherif; Jean-Paul Iyombe-Engembe; Antoine Guyon; Joel Rousseau; Dominique L Ouellet; Xavier Barbeau; Patrick Lague; Jacques P Tremblay
Journal:  Mol Ther       Date:  2018-08-16       Impact factor: 11.454

Review 4.  Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine.

Authors:  Nalinda B Wasala; Shi-Jie Chen; Dongsheng Duan
Journal:  Expert Opin Drug Discov       Date:  2020-01-30       Impact factor: 6.098

Review 5.  Correction of muscular dystrophies by CRISPR gene editing.

Authors:  Francesco Chemello; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 6.  Therapeutic approaches for cardiac regeneration and repair.

Authors:  Hisayuki Hashimoto; Eric N Olson; Rhonda Bassel-Duby
Journal:  Nat Rev Cardiol       Date:  2018-10       Impact factor: 32.419

Review 7.  Gene therapy strategies in the treatment of hypertrophic cardiomyopathy.

Authors:  Maksymilian Prondzynski; Giulia Mearini; Lucie Carrier
Journal:  Pflugers Arch       Date:  2018-07-03       Impact factor: 3.657

8.  Questions Answered and Unanswered by the First CRISPR Editing Study in a Canine Model of Duchenne Muscular Dystrophy.

Authors:  Nalinda B Wasala; Chady H Hakim; Shi-Jie Chen; N Nora Yang; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2019-02-26       Impact factor: 5.695

Review 9.  CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.

Authors:  Dan Wang; Feng Zhang; Guangping Gao
Journal:  Cell       Date:  2020-04-02       Impact factor: 41.582

10.  Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for In Vivo CRISPR/Cas-Based Genome Editing.

Authors:  Tuo Wei; Qiang Cheng; Lukas Farbiak; Daniel G Anderson; Robert Langer; Daniel J Siegwart
Journal:  ACS Nano       Date:  2020-07-22       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.